TAE术后白介素-2联合生脉注射液治疗肝癌临床观察

Clinical observation on SIL-Ⅱand Shenmai injection in treating liver malignancy after transcatheter arterial embolization

目的 观察白介素 2合并生脉注射液治疗肝癌栓塞化疗后近期疗效、生存率及免疫功能变化等临床指标。方法 采用已确诊的原发性及转移性肝癌 14 4例 ,随机分为治疗组及对照组各 72例 ,治疗组在采用肝癌栓塞化疗后即用白介素 2 2 0万U肌注 ,5 %GS2 5 0ml +生脉注射液 40ml静脉滴注 ,1/日 ,10～ 15天为 1疗程。对照组仅作栓塞化疗 ,两组病人行栓塞化疗 2～ 6次不等 ,间隔时间视病情而定。结果 治疗组有效率 (CR +PR)为 84.7( 61/72 ) ,明显高于对照组( 5 8.3 % ,42 /72 ) ;治疗组 1年、2年、3年生存率分别为 80 .5 %、66.7%、3 5 .4% ,中位生存期为 18个月 ,而对照组分别为 47.2 %、3 1.9%、13 .8% ,中位生存期为 10个月。两组比较有非常显著性差异 (P <0 .0 1) ;自然杀伤细胞 (NK)活性、T细胞亚群 (CD3 、CD4 、CD8、CD4 /CD4 )数值 ,在治疗后治疗组明显提高 ,对照组下降 ,两组有显著差异性 (P <0 .0 5 )。结论 生脉注射液联合白介素 2治疗肝癌栓塞化疗 ,有效率、生存率、中位生存期、免疫指标均较单纯栓塞化疗为高 ,是治疗中晚期肝癌较理想的方法。

? Objective To observe the clinical effect of SIL Ⅱ and shenmai injection on short term therapeutic effectiveness,survival rate and immunologic function of patients with liver malignancy after transcather avterial embolization.Methods 144 cases of comfirmed liver cancer were randomly and equally allocated into treating group and control group.The treating group were given SIL Ⅱ 2×10 6um.q.d.and 5% G.S.250ml+Shenmai injection 40ml vgtt.q.d,10～15 days forming one therapeutic course.The control group were only given chemotherapy combined with embolization Two groups were both given chemotherapy and embolization from 2 to 6 times.Intermittence was decided by the patient′s condition.Results The effective rate of the treating group (CR+PR) was 84.7%(61/72),which was much higher than that in the control group (58.3% 42/72).The survival rate of one,two and three years was 80.5%,66.7% and 35.4% respectively in the treating group.The medium survival rate was 18 months.But they were 47.2%,31.9% and 13.8% in the control group and the medium survival rate was 10 months.The two groups had a significant difference (P<0.01).The activity of NK,CD 3,CD 4,CD 8 and CD 4/CD 8 improved in the treating group after treatment.They decreased in the coutrol group with a significant difference (P<0.05).Conclusions Shenmai injection and SIL Ⅱ improve effective rate,survival rate,mediam survival rate and immunologic function in treating liver cancer after chemotherapy combined with embolization. So it is an ideal method to treat medium and advanced stage liver cancer. 〔